Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018)

Haematologica. 2007 Apr;92(4):568-9. doi: 10.3324/haematol.10797.

Abstract

We conducted a two-stage phase II study to investigate the activity of bortezomib and dexamethasone in patients with relapsed Hodgkin's lymphoma. The study was prematurely closed after the first stage with twelve enrolled patients because no response was observed. A meta-analysis of all four available studies evaluating bortezomib in this population showed no activity of bortezomib (combined response rate: 0.03; 95%-CI: 0.01 to 0.12).

Trial registration: ClinicalTrials.gov NCT00148018.

Publication types

  • Clinical Trial, Phase II
  • Comparative Study
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Boronic Acids / administration & dosage
  • Boronic Acids / adverse effects
  • Bortezomib
  • Dexamethasone / administration & dosage
  • Dexamethasone / adverse effects
  • Female
  • Hodgkin Disease / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Pyrazines / administration & dosage
  • Pyrazines / adverse effects
  • Recurrence
  • Salvage Therapy
  • Treatment Failure

Substances

  • Boronic Acids
  • Pyrazines
  • Bortezomib
  • Dexamethasone

Associated data

  • ClinicalTrials.gov/NCT00148018